<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/236E9A76-AEE2-49C8-BB8D-A33E9556D65A" ns1:id="236E9A76-AEE2-49C8-BB8D-A33E9556D65A"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/7B9D2485-3A05-4DFC-9059-BEC8DF2CFBC7" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/739F414B-2822-499B-B186-12735F7042DF" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/739F414B-2822-499B-B186-12735F7042DF" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2023-08-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/A0F75467-288C-4764-96E7-237391A6C6E7" ns1:rel="FUND" ns1:start="2022-03-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10021980</ns2:identifier></ns2:identifiers><ns2:title>Development of odour-based non-invasive diagnostics (NID) for infectious diseases to deliver affordable, accurate and accessible diagnosis</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>There are no changes to the published description, as detailed below:

Many infectious diseases cause changes in human body odour, generating a profile that can potentially be used for rapid, low-cost and non-invasive diagnosis. Arctech Innovation is building on early research to create a breakthrough diagnostic platform utilising electronic sensors to accurately detect the unique profiles from infected individuals.

This project focuses on prototype diagnostic device development with malaria as an initial proof-of-concept, to validate Arctech Innovation's approach and address a critical need for improved methods of early-stage diagnosis and detecting asymptomatic/mild malaria infections that are frequently undetected or misdiagnosed. It builds on extensive analytical chemistry studies and Arctech Innovation's initial sensor evaluation/assessment, which show feasibility of detecting malaria at an earlier stage than is currently possible and when infection levels are lower.

This game-changing solution will deliver wide-ranging socio-economic benefits to globally-disadvantaged groups. Worldwide, there were ~229m malaria cases and ~409,000 deaths during 2019 in 87 countries. Despite previous success, progress against malaria has stalled, and WHO morbidity and mortality reduction targets will be missed whilst the economic direct/indirect costs are vast. Further progress requires addressing key challenges such as improved methods for early-stage diagnosis (2 weeks prior to late-stage diagnosis) and detecting asymptomatic individuals that can still transmit malaria parasites and may account for up to 50% of onward transmission.

The malaria diagnostics market (2020 value ~&amp;pound;800m) increasingly demands early diagnosis and surveillance systems in developing countries, representing a significant export opportunity. The wider infectious diseases market is a much larger opportunity thus demonstrating the potential value of our technology.</ns2:abstractText></ns2:project>